Samples from 51 chronic lymphocytic leukaemia (CLL) patients (42 typical, nine atypical) were assessed for in vitro response to fludarabine and cladribine (2-CdA) using the flow cytometric terminal deoxynucleotidyl transferase (TdT) assay. No difference was demonstrated between the in vitro response of typical and atypical CLL and previous treatment did not result in a more apoptosis resistant phenotype. The assay could not distinguish those patients who required subsequent treatment from those whose disease remained stable, and universal cross-resistance/sensitivity to the two purine analogues was demonstrated. The assay's potential for use in the rapid assessment of in vivo response to purine analogue therapy in CLL was limited; correctly predicting the clinical outcome of 10/12 patients to treatment but failing to predict progression in two p53 deficient patients. The level of bcl-2 in the clonal lymphocytes did not influence the in vitro, spontaneous or drug-induced, apoptosis.
Introduction
Drugs of the purine analogue group have considerable clinical efficacy in the treatment of low-grade lymphoproliferative diseases and there is extensive experience with the use of fludarabine and cladribine to treat patients with chronic lymphocytic leukaemia (CLL). 1 Both compounds are resistant to deamination by adenosine deaminase within lymphoid cells resulting in their incorporation as abnormal nucleotides into DNA 2, 3 and cell death by apoptosis. 4 Various assays have been applied to the assessment of the in vitro chemosensitivity of CLL cells [5] [6] [7] and the suggestion that the susceptibility of cells to the induction of apoptosis may correlate with the clinical response to purine analogue therapy has been made. 5 As cell death due to purine analogue treatment results from the production of DNA strand breaks, the terminal deoxynucleotidyl transferase (TdT) assay should be an appropriate method for assessing chemosensitivity in these patients. TdT is a DNA polymerase which can be used to label DNA strand breaks by the incorporation of a labelled nucleotide followed by a fluorescent detection step. 8 Exposure to therapeutic agents may result in changes in the chemosensitivity of CLL cells. In vitro studies of previously treated CLL patients have reported the development of pleiotropic drug resistance 9 and a difference in the spontaneous rate of apoptosis. 5 Other investigators have demonstrated that in vitro resistance to chlorambucil increased following chlorambucil therapy. 10 However, in some cases, the increase was reversible and fluctuations in untreated patients could occur, suggesting that factors other than therapy influence drug resistance.
Clinical evaluations of the comparative efficacy of purine analogues have produced inconsistent results with some reports of responses with one agent after failure with the other, 11 while the experience of others is that clinical resistance extends to both compounds. [12] [13] [14] In vitro, a correlation of resistance/sensitivity between 2-CdA and fludarabine was found in a proportion of CLL samples (54/78). 15 This study also reported a correlation of drug resistance with expression of the FMC7 antigen. The association of this marker with non-CLL malignant lymphoid disorders suggests that disease entities which are intrinsically less likely to be responsive to purine analogue therapy may have been included in the analyses. Consistent classification of lymphoproliferative disorders is of great importance when correlating laboratory parameters with clinical course, as inclusion of a heterogeneous group of patients will obscure emerging trends. In this report, strict morphological and immunophenotypic criteria have been used to define the patient population and inclusion has been restricted to CLL only. 16 A recent report suggested that atypical CLL was more likely to progress clinically than typical CLL, 17 implying that some fundamental difference exists between these two subtypes of disease. The present belief that CLL arises through a defect in the apoptotic pathway raises the question as to whether typical and atypical CLL show similar apoptotic responses, and led to the further classification of patients in this report as typical and atypical CLL.
The over-expression of the oncogene bcl-2, a well established characteristic of CLL cells 18 arises from hypomethylation of the bcl-2 gene and has been linked with the extended survival of CLL cells in culture. 19 A study of CLL patients found no correlation of bcl-2 expression and clinical features, however, higher bcl-2 levels appeared to be linked with shorter survival. 20 The belief that the level of bcl-2 can, by itself, predict the susceptibility of a sample to apoptosis is losing favour since the discovery of a bcl-2-related gene bax. The proposition that the ratio of bcl-2 to bax determines cell survival rather than the absolute level of either has been made. 21 We have applied the TdT assay to 51 patients with CLL and evaluated the level of bcl-2 in their clonal lymphocytes. Correlation of TdT assay results with the level of bcl-2 protein expression was examined.
Materials and methods

Patients
Peripheral blood (PB) samples from 51 B-CLL patients were examined. All patients had a significant lymphocytosis; at the time of study the majority of the lymphocytes were malignant. Strict criteria were applied to define the diagnosis and patients were classified as typical CLL or atypical CLL according to surface immunophenotype and morphology 16 22 and response criteria were defined by the NCI-sponsored working group. 23 
Drug sensitivity assay
Peripheral blood mononuclear cells were obtained by density gradient centrifugation on lymphocyte separation medium (Nycomed, Oslo, Norway). Aliquots of 10 6 cells were cultured in a total volume of 500 l RPMI 1640, 25 mm Hepes with lglutamine (Life Technologies, Paisley, UK), 10% fetal calf serum (Life Technologies), in a 37°C, 5% CO 2 , humidified incubator in the presence/absence of drug. Drug concentrations used were fludarabine (Schering AG, Berlin, Germany) 3 m and 30 m, cladribine (purchased from Drs Zygmunt Kazimierczuk and Pawel Grieb, The Foundation for the Development of Diagnostics and Therapy, Warsaw, Poland) 1.7 m and 17 m. After 22 h culture, cells were centrifuged out of media at 200 g, fixed in 1% formaldehyde (made fresh from a 4% stock solution) for 15 min on ice, washed in PBS (pH 7.4) and resuspended in 70% ethanol. The samples were kept at −20°C for 1-3 days before performing the TdT assay. The DNA strand breaks were labelled with digoxigenin-ddUTP (Boehringer Mannheim, Lewes, UK) and detected using FITC conjugated anti-digoxigenin (Boehringer Mannheim). 24 Samples were analysed on a FACScan flow cytometer (Becton Dickinson, Oxford, UK) using a 488 nm beam from an argon ion laser. Green fluorescence was collected after a 530 nm (band width 30 nm) filter and measured using logarithmic amplification. Calibration and sensitivity were checked using fluorescent-labelled beads (Calibrite Beads; Becton Dickinson). Debris was gated out on the forward scatter vs side scatter dot plot and 10 000 events collected. The data were analysed using LYSIS II software (Becton Dickinson).
Background fluorescence was determined using a patientspecific sample fixed pre-culture and a region corresponding to increased green fluoresence set. The percentage of cells responding was taken as those showing increased green fluorescence.
Duplicate wells were analysed in several patients, the variation in percentage of cells responding was such that in the remaining patients only a single assay was performed. 
Statistical analysis
Patient groups were compared with the Mann-Whitney U test, the significance of response to drug analysed by Wilcoxon signed rank test and the relationship between response to cladribine and fludarabine was compared using Spearman correlation. All analysis was performed using SPSS PC + software.
Results and discussion
Drug sensitivity assay
Previous investigators have demonstrated that a substantial proportion of PB B-CLL lymphocytes die spontaneously by apoptosis upon culture, 25 that this could be increased by the addition of purine analogue to the culture, and that interpatient variation occurred. 5 Using the TdT assay to assess in vitro response of CLL cells to culture and exposure to purine analogues, cladribine and fludarabine, we report that this cohort of CLL patients exhibited widely varying responses. Addition of cladribine or fludarabine resulted in a dosedependent increase in apoptosis. Statistical analysis showed the response to addition of drug to be significant for both concentrations of fludarabine and cladribine (Wilcoxon signed rank test P = 0.000 in all cases). This analysis was repeated on all subsets of patients subsequently analysed and the significance remained. Although the higher concentrations of drug used (fludarabine 30 m, cladribine 17 m) are higher than that therapeutically achievable, a complete range of response was seen between the patients (30 m fludarabine range 14-91%, 17 m cladribine range 13-94%) with both extremes being rare. As our aim was to identify comparative differences between patients and the higher drug concentrations exaggerated the effect rather than turning comparative non-responders into responders, we restricted our analyses to the high concentrations.
Clinically, fludarabine is administered as fludarabine monophosphate which is rapidly dephosphorylated to the nucleoside F-ara-A, by 5Ј-nucleotidase, before transportation into the cell and rephosphorylation to its tri-phosphate form. A concern with using the monophosphate form (fludarabine) in an in vitro system is that transport of the drug into the cells will be impaired. However, in our system the drug had an effect on lymphocytes and the effect was dose dependent indicating that the drug had access to the cells. For some patients whole blood cultures were set up in parallel with cultures of separated lymphocytes and no difference in the percentage of cells responding to fludarabine was observed, indicating that 5Ј-nucleotidase activity on erythrocytes did not increase the availability of fludarabine to cells in this assay. Due to the relative insolubility of F-ara-A and the results of these preliminary experiments fludarabine was used in this assay. In this cohort of strictly classified CLL patients the rates of spontaneous apoptosis and response to fludarabine and cladribine showed wide variation and no significant difference was apparent between patients with typical or atypical CLL (Table  2 ). Atypical CLL is clinically more aggressive than typical CLL, 17 however, the results presented here imply that atypical CLL lymphocytes are not more resistant to the in vitro induction of apoptosis. When the effect of prior treatment was examined, 13 patients who had completed therapy more that 6 months before assessment (but with significant disease present) were compared with 35 previously untreated patients (one patient receiving treatment immediately prior to the assay was excluded from analyses); analyses showed no statistically significant difference (Mann-Whitney U test) between the two groups for either spontaneous or drug-induced response (Table 3A ). It appears from these results that chemotherapy does not necessarily result in the irreversible selection of a lymphocyte subpopulation more resistant to apoptotic cell death. This is in conflict with previous reports 5,9,10 although the latter investigators found that in some cases the increase was reversible and that fluctuations in untreated patients could also occur. Our group of previously treated patients had all received treatment over 6 months before the assay was performed; this may explain the discrepancy between findings and also supports the suggestion that factors other than therapy cause changes in drug resistance.
Comparison of previously untreated patients who subsequently required treatment (n = 10) with those who have never needed treatment (n = 25) showed no statistically significant differences (Mann-Whitney U test) in their in vitro response (Table 3B ); demonstrating that this in vitro assay is not capable of distinguishing the subset of CLL patients who will require future treatment from those whose disease remains stable. This is an interesting observation, implying that the susceptibility of CLL cells to apoptosis in vitro bears little relation to their accumulative potential in vivo.
The correlation between the in vitro response of patients to cladribine and fludarabine was striking (Figure 1 ), only 2/51 patients varied in their response to the two drugs (P = 0.000 by Spearman correlation analysis). Previous investigators have documented a general concordance of sensitivity to 2-CdA and fludarabine but did find a percentage of cases where cross-resistance was not evident. 15 The use of cut off LD 50 values for placing patients into sensitive/resistant categories in that report, however, may result in slight variations leading to misleading classification. The results presented here suggest that the two purine analogues can be used interchangeably and that clinical considerations should carry more weight than preferential sensitivity. Study of the 13 CLL patients who received purine analogue therapy (patient details Table 4) following the in vitro assay showed the assay to be a general guideline to clinical response. Patient 13 had not completed treatment at the time of writing and hence is excluded from further consideration. The clinical and in vitro response of the remaining twelve patients was compared (Figure 2) . Culturing in the absence of drug held no predictive value, however, when the responses to addition of fludarabine and cladribine were considered and a cut off set at 20% of cells responding, the assay correctly forecast the clinical response in 10/12 patients. The assay failed in two patients (patients 8 and 12), predicting a response, when in both patients the disease actually progressed while on therapy, a major drawback as these are the patients it would be most useful to identify. Patient 12, however, only received two courses of fludarabine before having to be withdrawn from treatment due to concurrent medical problems and so may have had an inadequate trial of treatment.
These failings highlight the importance of monitoring defects in apoptosis controlling genes alongside the in vitro assay. Mutations of p53 have been reported to be associated with a poor response to purine analogue therapy in CLL. 26 Western blot analyses suggested that patient 8 could not induce expression of p53 on exposure to drug and that patient 12 expressed mutant p53 (data not shown). The TdT assay indicates the level of DNA strand breaks within a sample, if p53 is non-functional it is possible that cells could accumulate DNA strand breaks without being able to enter apoptosis 27 and this would appear to explain the anomalous results in these two patients. The assay correctly predicted one patient resistant to therapy (patient 1) with less than 20% of cells showing a response to cladribine or fludarabine. Although the patient group is too small to draw conclusions from, it may be that the use of this assay alongside p53 assays could provide a helpful guideline.
Comparison of Bcl-2 protein level and in vitro response to drug
The level of bcl-2 protein expression did not vary significantly between the two subtypes of CLL (typical CLL range 117-382, median 226; atypical CLL range 131-400, median 248.5). The level of bcl-2 in lymphocytes did not correlate with the in vitro, spontaneous or drug-induced apoptosis in this group of patients ( Figure 3) .
The lack of influence of bcl-2 levels on the in vitro response of lymphocytes in this study supports the belief that the level of bcl-2 expression by itself is not a good predictive factor of susceptibility to apoptosis and that level of bcl-2 should be considered alongside those of bax. Although levels of bcl-2 alone have been reported to be inversely related with survival, 20 drug resistance in B-CLL seems more dependent on the ratio of bcl-2:bax. 28 Unintentional inclusion of NHL would bias results such as these. This study, as stated earlier, includes only strictly classified CLL. We are now beginning an investigation of bcl2:bax ratios in our current CLL patient population.
In conclusion, although this in vitro TdT assay appears to give a guide to response to purine analogue therapy in most patients it can be misleading in those with defects in p53 and cannot identify at diagnosis those patients who will require treatment at a later date. These results highlight the importance of monitoring apoptosis controlling genes and the search for new genetic markers of poor prognosis in CLL.
